RecruitingNCT06141811
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
Sponsor
Anterogen Co., Ltd.
Enrollment
104 participants
Start Date
Apr 25, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months
Eligibility
Min Age: 19 YearsMax Age: 75 Years
Inclusion Criteria2
- Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-302.
- Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria1
- \. Subjects who are considered not suitable for the study by the principal investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALALLO-ASC-DFU
Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
PROCEDUREVehicle sheet
Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06141811
Related Trials
Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers
NCT069386858 locations
Diabetes Related Foot Ulcers With Negative Pressure Wound Therapy
NCT067217542 locations
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
NCT063830135 locations
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
NCT065150932 locations
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers
NCT070393963 locations